{"paper_id":"7f6f8056-1dfc-4b2b-b712-bce8d39b39ac","body_text":"PRLR drug-target Mendelian randomization for endometriosis\nAuthors/Creators\nDescription\nThis repository contains the complete analysis code, data, figures, and\nsubmission-ready manuscript for a drug-target Mendelian randomization (MR)\nstudy of the prolactin receptor (PRLR) and endometriosis risk.\nStudy summary:\nUsing cis-eQTL instruments for PRLR from eQTLGen (primary instrument\nrs6451196), we performed drug-target MR for endometriosis across FinnGen\nreleases (R8-R13), with replication in UK Biobank, the Sakaue 2021\ncross-population meta-analysis, the Rahmioglu 2023 European meta-analysis\n(GCST90205183), and BioBank Japan. Findings were validated by colocalisation\n(PP.H4=90.6%), SMR+HEIDI, and GTEx tissue eQTL analyses. Genetically predicted\nhigher PRLR expression was associated with increased endometriosis risk\n(FinnGen R13: beta=0.227, 95% CI 0.136-0.317, P=7.1e-7; OR=1.26).\nContents:\n- scripts/: analysis scripts (Python/R) for MR, colocalisation, SMR+HEIDI,\nsensitivity, and figure generation\n- results/: analysis outputs and summary tables\n- manuscript/: submission-ready manuscript\n- manuscript_ebiomedicine_reformatted_fixed.md/.docx: final main text\n- supplementary_reformatted_fixed.md/.docx: supplementary materials\n- figures_final/: main figures (Figure 1-5) in editable PDF and 300-dpi PNG\n- supplementary_figS1-S3: supplementary figures\nAll analyses used publicly available summary-level data. Please cite the\nassociated manuscript upon publication.\nFiles\nPRLR_EMs_zenodo_archive_2026-08-11.zip\nFiles\n(11.1 MB)\n| Name | Size | Download all |\n|---|---|---|\n|\nmd5:576fcde4ad57568b880a8b1cccb55ba1\n|\n11.1 MB | Preview Download |","source_license":"CC0","license_restricted":false}